‘Next wave of IPOs’ will arrive in summer, predicts biotech-focused VC partner

Delegates at the LSX World Conference in London this week seemed to agree on one thing—the biotech IPO window finally re-opened this year. This sentiment has persisted despite the fact that the initial run of public offerings died down by the spring.

For Francesco De Rubertis, co-founder and partner of London-based life sciences investment firm Medicxi, the current lull is to be expected. What’s more, he expects “at least a number of IPOs” to arrive as soon as the summer.